NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- State
- Completed
- Phase
- Phase 2
- People
- 626 taking part
- Started
- 1 Apr 2024
- Primary completion
- 24 Sep 2025
- Arms
- Cagrilintide
- Results
- None posted
- 14 Nov 2023: Trial registered
- 1 Apr 2024: Trial started
- 6 Nov 2025: Trial completed